Biotech Values

[DewDiligence]

WSJ’s lead paragraph on MAKO deal is a non sequitur (IMO):

http://online.wsj.com/article/SB10001424052702303796404579096981814533534.html

Stryker Corp. agreed to acquire Mako Surgical Corp. and its robotic-surgery platform for roughly $1.65 billion, a move aimed at distinguishing Stryker's line of replacement knees and hips for its increasingly cost-conscious hospital customers.

SYK’s knees don’t work any better with the MAKO procedure than ZMH’s knees or DePuy’s knees. Maybe they will at some point, but there’s no immediate technical synergy.